Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical company that focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company reports that it currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions, and it is based in Scottsdale, Arizona.
The news flow around Journey Medical often centers on its dermatology portfolio and, in particular, Emrosi (DFD-29), an FDA-approved low-dose oral minocycline formulation indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Company press releases highlight clinical trial milestones, such as pooled Phase 3 efficacy analyses demonstrating statistical superiority of DFD-29 versus placebo and an active comparator, as well as Phase 1 data published in the Journal of Drugs in Dermatology showing no detectable impact on skin, gastrointestinal or vaginal microbiota over 16 weeks in healthy adults.
Investors following DERM news can also expect updates on quarterly financial results, revenue trends, and the commercial performance of Emrosi and other branded dermatology products. Journey Medical regularly issues releases on its net product revenues, gross margin metrics, and developments such as expanded payer access for Emrosi and inclusion in the Russell 2000 and Russell 3000 indices. Additional news items may cover corporate events, investor conference participation, credit agreement amendments, and capital markets activities disclosed through SEC filings and press announcements.
This news page aggregates Journey Medical’s press releases and related coverage so readers can review developments in its dermatology product portfolio, clinical data presentations, and public company updates in one place.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is set to take place on Wednesday, October 9, 2024, in New York City.
Members of Journey Medical's management team will be attending one-on-one meetings during the conference. This participation highlights the company's commitment to engaging with investors and industry professionals in the healthcare sector.
The conference provides an opportunity for Journey Medical to showcase its focus on selling and marketing dermatological treatments, potentially attracting investor interest and fostering business relationships within the pharmaceutical industry.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference. The event is set to take place on Thursday, September 12, 2024 in New York City.
Claude Maraoui, President and CEO of Journey Medical, will be attending the conference to engage in one-on-one meetings with investors and industry professionals. This participation underscores the company's commitment to growth and investor relations in the pharmaceutical sector, particularly in the field of dermatology.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Claude Maraoui, President and CEO, will present a corporate overview available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET.
The company will also engage in one-on-one meetings during the conference. Investors can access a replay of the presentation on Journey Medical's website for approximately 30 days after the event, providing an opportunity to gain insights into the company's strategies and performance in the dermatological pharmaceutical market.
Journey Medical (Nasdaq: DERM) reported financial results for Q2 2024. Key highlights include:
- Total revenues of $14.9 million, a 14% increase from Q1 2024
- Net loss reduced by $5.0 million to $3.4 million or $(0.17) per share
- Positive Adjusted EBITDA of $0.3 million
- Cash and cash equivalents of $23.9 million as of June 30, 2024
The company's New Drug Application for DFD-29 to treat rosacea is under FDA review with a PDUFA goal date of November 4, 2024. Journey Medical appointed Joseph M. Benesch as CFO and Michael C. Pearce to its Board of Directors. The company remains on track to deliver its 2024 financial guidance.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focusing on FDA-approved dermatological treatments, has announced it will release its second quarter 2024 financial results on August 12, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). Participants can also register online to receive a dial-in number. A live audio webcast will be available on the company's website and will remain accessible for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM) has appointed Michael C. Pearce to its Board of Directors, effective July 9, 2024. Pearce, an experienced principal investor and advisor in the healthcare sector, has an extensive background, including roles at EP Group, Evening Post Industries (EPI), and as Chairman of Range Therapeutics. His appointment comes as Journey Medical approaches the potential FDA approval of DFD-29, a promising treatment for rosacea, in November 2024. Pearce's strategic, business, and financial expertise is expected to bring significant value to Journey Medical's leadership as it continues to pursue its corporate goals.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, announces its participation in the Alliance Global Partners’ Virtual Healthcare Company Showcase.
CEO Claude Maraoui will participate in a fireside chat on May 21, 2024, at 1:00 p.m. ET. The event will provide insights into the company's operations and future plans.
Registration for the conference is available online, and a replay of the chat will be accessible on Journey Medical’s website for 30 days after the event.
Journey Medical (Nasdaq: DERM) reported a 7% year-over-year increase in total revenues for Q1 2024, reaching $13 million. This growth was driven by significant increases in the sales of Qbrexza and Accutane, despite declines in other products like Amzeeq and Zilxi. The company reported a net loss of $10.4 million, slightly higher than the $10.1 million loss in Q1 2023. Research and development expenses surged due to a $4 million FDA filing fee and a $3 million milestone payment. Journey Medical's New Drug Application for DFD-29 to treat rosacea has been accepted by the FDA, with a PDUFA goal date of November 4, 2024, potentially making it a leading systemic therapy for rosacea.
Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.
Journey Medical has appointed Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Benesch brings over 25 years of experience in financial leadership and reporting, with a focus on the pharmaceutical industry. The company's Co-Founder, President, and CEO praised Benesch's expertise and contributions to the finance and accounting team, emphasizing his role in upcoming milestones like the potential approval of DFD-29 for rosacea treatment. Benesch's extensive background includes positions at Teligent Pharma Inc., Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals, along with experience at Baker Tilly Virchow Krause, LLP, and Ernst and Young. With a BA in accounting and CPA certification from Wilkes University, Benesch aims to drive sustainable value for Journey Medical and its shareholders while supporting patients with dermatological products.